Stoke Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
STOK Nasdaq 2836 www.stoketherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Jan 16th, 2026 2:01 pm
High Growth US Tech Stocks To Watch In January 2026 - Jan 13th, 2026 10:38 am
Sector Update: Health Care Stocks Mixed Late Afternoon - Jan 12th, 2026 1:50 pm
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Jan 11th, 2026 12:00 pm
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 2:01 pm
Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Dec 29th, 2025 12:20 pm
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% - Dec 16th, 2025 11:15 am
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - Dec 10th, 2025 7:19 pm
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Dec 6th, 2025 5:08 pm
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Dec 5th, 2025 7:00 am
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Dec 5th, 2025 7:00 am
A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge - Dec 2nd, 2025 12:11 pm
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Dec 1st, 2025 5:30 am
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Dec 1st, 2025 5:30 am
Biotechs Are On A Big Run, And Two Stocks Have Buy Points - Nov 28th, 2025 8:07 am
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results - Nov 18th, 2025 11:17 am
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Nov 17th, 2025 5:30 am
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Nov 17th, 2025 5:30 am
High Growth Tech Stocks In The US Market November 2025 - Nov 6th, 2025 10:38 am
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Nov 5th, 2025 2:01 pm